What Manual Literature Reviews Cost, and Where the Money Goes Manual systematic literature reviews remain the backbone of evidence-based decisions in healthcare, policy, and research. Teams follow strict protocols, search multiple databases, screen thousands of records, extract data by hand, and synthesize findings. The method delivers high-quality results. Yet the true price of this work…
Why the Systematic Literature Review Timeline Still Runs Into Months A typical systematic literature review (SLR) timeline is measured in quarters, not weeks, and the reason is rarely a lack of effort. Borah and colleagues tracked reviews registered on PROSPERO and found a median of 67.3 weeks from registration to publication (BMJ Open, 2017). As…
Consider a cross-functional team huddled around spreadsheets, regulatory guidelines, and past trial data, spending weeks or sometimes months crafting a single clinical trial protocol; see protocol structure details. Every inclusion criterion, endpoint, and safety measure must align perfectly with ICH-GCP standards, FDA expectations, and real-world feasibility. One misalignment, and you risk costly amendments, delayed starts,…
Background: Scientific Data Review Evidence volumes are rising, but review teams are not. In 2010, the scientific community published roughly 75 trials and 11 systematic reviews daily, and this pace has only accelerated. Today, more than 200 new systematic review protocols are registered in PROSPERO every day, illustrating how demand for evidence synthesis has outpaced…
Scaling Patient-Reported Outcomes In the world of clinical research and drug development, patients’ own voices matter more than ever. Patient-reported outcomes (PROs) capture how people actually feel, their symptoms, quality of life, side effects, and daily functioning. Yet turning these often messy, free-text or survey responses into clean, structured data that regulators can trust has…
HTA-Ready Evidence Dossiers HTA (Health Technology Assessment)-ready evidence dossiers represent a critical deliverable for HEOR teams seeking market access and reimbursement for new therapies. These documents compile clinical, economic, and real-world evidence to meet strict requirements from health technology assessment bodies such as NICE, CADTH, or HAS. HTA-ready evidence dossiers demand more data, tighter timelines,…
